BioLineRx Announces Initiation of Triple Combination Arm of Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer Under Immuno-Oncology Collaboration

As previously announced, the triple combination arm will investigate the safety, tolerability and efficacy of BL-8040, KEYTRUDA and chemotherapy. The triple combination arm will focus on second-line p...

NOXXON To Present Latest Clinical Data from Nox-A12 / Keytruda® Combination Trial at Esmo Immuno-Oncology Congress on Decemb...

NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today the details of its part...

Oncosec Medical (ONCS) Announces Updated Tumor Responses in KEYNOTE-695 Study of TAVO Plus KEYTRUDA in Refractory Metastatic Melanoma

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. OncoSec Medical Incorporated (NASDAQ: ONCS) today announced an update regarding tumor re...